NCT04855435View on ClinicalTrials.gov

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

MBS8(1V270)

The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.

Trial Locations (5)

1070

RECRUITING

Institut Jules Bordet, Anderlecht

28015

RECRUITING

Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD), Madrid

28050

RECRUITING

Centro Integral Oncológico Clara Campal (CIOCC), Madrid

DK2100

RECRUITING

University Hospital of Denmark, Department of Oncology, Copenhagen

DK-2730

RECRUITING

Herlev and Gentofte Hospital, Center for Cancer Research, Herlev

Sponsors
All Listed Sponsors
lead

MonTa Biosciences ApS

INDUSTRY

NCT04855435 - Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter